Optomed Oyj - Inside information

Optomed upgrades its outlook for 2021 due to improved market sentiment and very strong start of the year

Optomed Plc         Inside Information              8 April 2021 at 19.30,
Helsinki

Optomed upgrades its outlook for 2021 due to improved market sentiment and very
strong start of the year

Optomed upgrades its outlook for 2021 due to improved market sentiment and very
strong growth during the first quarter of the year.


Seppo Kopsala, Optomed CEO, comments:

“Optomed has started the year with very strong growth. Overall, the COVID-19
pandemic has accelerated the transformation of the diagnostic process towards
remote monitoring and screening. For example, diabetics are considered to belong
to the COVID-19 high risk group, and it is not recommended for them to visit
crowded hospitals or eye clinics for their routine annual eye examinations. This
has made handheld fundus cameras very attractive for many clinics and screening
operators since they need new diagnostic equipment to treat their patients in a
remote way. This transformation seems to be moving eye screening more towards
primary care clinics, especially in the US market. The visibility to H2 remains
low due to the pandemic, but currently it seems like the ongoing transformation
of the fundus camera market towards portable cameras and remote screenings using
telemedicine and AI grading is accelerating our growth in 2021.”
The updated outlook for 2021:

Optomed expects its full year 2021 revenue to grow strongly compared to 2020.



The previous outlook for 2021 (announced 18 February 2021):

Optomed expects its full year 2021 revenue to grow compared to 2020.

Optomed will publish the Interim Report for January-March 2021 on 6 May 2021.


Optomed Plc

Further enquiries

Seppo Kopsala, CEO, Optomed Plc,
seppo.kopsala@optomed.com (seppo.kopsala@optomed.com)


Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye-screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries. The
company has an extensive portfolio of over 50 international patents protecting
the technology.